These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Immunotherapy of malignant gliomas. Jaeckle KA Semin Oncol; 1994 Apr; 21(2):249-59. PubMed ID: 8153668 [No Abstract] [Full Text] [Related]
4. The biological significance of the immune response with special reference to parasites and cancer. Davies AJ; Hall JG; Targett GA; Murray M J Parasitol; 1980 Oct; 66(5):705-21. PubMed ID: 7463241 [No Abstract] [Full Text] [Related]
5. BCG immunotherapy of bladder cancer: 20 years on. Alexandroff AB; Jackson AM; O'Donnell MA; James K Lancet; 1999 May; 353(9165):1689-94. PubMed ID: 10335805 [No Abstract] [Full Text] [Related]
6. [Cancer immunotherapy targeting WT1 product which overexpressess in various kinds of malignant neoplasms]. Oka Y; Tsuboi A; Sugiyama H Tanpakushitsu Kakusan Koso; 2003 Aug; 48(11 Suppl):1663-70. PubMed ID: 12931627 [No Abstract] [Full Text] [Related]
7. Recombinant DNA virus vectors for vaccination. Moss B Semin Immunol; 1990 Sep; 2(5):317-27. PubMed ID: 2134016 [TBL] [Abstract][Full Text] [Related]
8. Immune checkpoints in viral latency. Redpath S; Angulo A; Gascoigne NR; Ghazal P Annu Rev Microbiol; 2001; 55():531-60. PubMed ID: 11544366 [TBL] [Abstract][Full Text] [Related]
9. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy. Merritt RE; Yamada RE; Crystal RG; Korst RJ J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342 [TBL] [Abstract][Full Text] [Related]
10. Adjuvant formulations and their mode of action. Allison AC; Byars NE Semin Immunol; 1990 Sep; 2(5):369-74. PubMed ID: 1966859 [TBL] [Abstract][Full Text] [Related]
11. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clay TM; Hobeika AC; Mosca PJ; Lyerly HK; Morse MA Clin Cancer Res; 2001 May; 7(5):1127-35. PubMed ID: 11350875 [TBL] [Abstract][Full Text] [Related]
15. Vaccine therapy using rgp 160 in early HIV infection. Redfield R; Birx D; Ketter N; Polonis V; Johnson S; Davis C; Smith G; Oster C; Burke D AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1333. PubMed ID: 1361350 [No Abstract] [Full Text] [Related]
16. How viruses suppress immunity. Lee RE Can Med Assoc J; 1984 Dec; 131(12):1437-42. PubMed ID: 6498697 [No Abstract] [Full Text] [Related]
17. Pathology during acute infections: contributions of intracellular pathogens and the CTL response. Ganusov VV; Antia R Biol Lett; 2005 Jun; 1(2):239-42. PubMed ID: 17148176 [TBL] [Abstract][Full Text] [Related]
18. Editorial: Transfer factor. Br Med J; 1974 May; 2(5916):397-8. PubMed ID: 4546097 [No Abstract] [Full Text] [Related]
19. Retroviral vectors as vaccines and immunotherapeutics. Jolly DJ; Warner JF Semin Immunol; 1990 Sep; 2(5):329-39. PubMed ID: 1966858 [TBL] [Abstract][Full Text] [Related]
20. Taking the first steps towards infection. Teitzel G Trends Microbiol; 2013 Aug; 21(8):359. PubMed ID: 23910544 [No Abstract] [Full Text] [Related] [Next] [New Search]